University Hospital Basel
Basel, Canton of Basel-City, 4031, Switzerland
NCT Number: NCT01790529
Surgical site infections (SSI) are the most frequent hospital acquired infections in patients who underwent surgery. With regards to the increasing financial restraint in patient care, the socio-economic burden of SSI in the public health sector and its prevention gains in importance.
The prophylactic application of antibiotics (surgical antimicrobial prophylaxis, SAP) prior to the skin incision significantly reduces the risk of SSI, but the correct time point of drug administration remains unclear. Most studies recommend application of SAP directly prior to skin incision. Other studies, however, suggest that this is too late and more time between administration of the SAP and skin incision is necessary for optimal SSI prevention. A large cohort study in Switzerland concluded that SAP should be applied between 74 and 30 minutes prior to skin incision.
Due to the obvious importance of this controversy, we want to answer this question with a clinical study (randomized controlled trial, RCT) at the University Hospital of Basel and the Cantonal Hospital of Aarau. We plan to investigate two administration strategies according to the timing of the SAP. Strategy A will consist of SAP application in the anesthetic room located in front of the actual operating theatre, where the patient gets anesthesia. Therefore, the application of SAP will take place early, approximately between 75 and 30 minutes prior to skin incision. In strategy B we will apply SAP in the operating theatre, which on average occurs later (approximately within the last 30 minutes before skin incision).
We test the hypothesis that strategy A is more effective in preventing SSI than strategy B. We will include a total of 5000 patients in abdominal, vascular and trauma surgery (2500 at each study site and 2500 per study group). All patients will be followed in the hospital for SSI occurrence. Additionally, all patients will be interviewed by telephone after hospital discharge at a defined follow-up period of 30 days (1 year if an implant is in place, such as hip endoprosthesis or meshes). We expect this study to be completed within approximately 3 years.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Basel, Canton of Basel-City, 4031, Switzerland
Additionally, the association between the following pre-defined variables and the occurence of SSI, mortality, morbidity and length of hospital stay (LOS) will be investigated:
Amendments:
The following changes were made to the study protocol according to amendments approved by the local ethics committee:
The following additional amendments were authorized by the ethics committees on August 9th, 2014:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 30 days
Surgical Site Infection within 30 days after index surgery
Time frame: 30 days
Time frame: 1 year
Time frame: 1 year
Time frame: 1 year
Time frame: 1 year
according to the Clavien-Dindo-Classification
Time frame: 1 year
Surgical Site Infection within 1 year after surgery only for implant surgeries
University Hospital, Basel, Switzerland
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04411199
Abdominal Surgery, Colon Surgery
Augusta, Georgia, United States
View Trial DetailsNCT04366440
Infections, Pathologic Processes
St. Petersburg, Florida, United States
View Trial DetailsNCT06108791
Infections, Pathologic Processes
Asyut, Egypt
View Trial DetailsNCT02734134
Infections, Pathologic Processes
Chicago, Illinois, United States
View Trial Details